Published in Int J Pharm on November 09, 2007
Systemically injected exosomes targeted to EGFR deliver antitumor microRNA to breast cancer cells. Mol Ther (2012) 2.15
Nanoparticles and the immune system. Endocrinology (2009) 1.79
Challenges in development of nanoparticle-based therapeutics. AAPS J (2012) 1.28
Polymer-drug conjugates: origins, progress to date and future directions. Adv Drug Deliv Rev (2012) 1.28
Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J Pharm Sci (2011) 1.24
Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther (2014) 1.10
Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J Drug Deliv (2013) 1.06
Development and characterization of chitosan-PEG-TAT nanoparticles for the intracellular delivery of siRNA. Int J Nanomedicine (2013) 0.96
Anti-PEG IgM Response against PEGylated Liposomes in Mice and Rats. Pharmaceutics (2010) 0.93
In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev (2015) 0.92
Advances and Challenges of Liposome Assisted Drug Delivery. Front Pharmacol (2015) 0.91
The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment. Expert Opin Drug Deliv (2010) 0.91
Non-PEGylated liposomes for convection-enhanced delivery of topotecan and gadodiamide in malignant glioma: initial experience. J Neurooncol (2009) 0.90
Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives. Int J Nanomedicine (2012) 0.90
Uricases as therapeutic agents to treat refractory gout: Current states and future directions. Drug Dev Res (2011) 0.89
The effect of cholesterol domains on PEGylated liposomal gene delivery in vitro. Ther Deliv (2011) 0.89
High-Density Lipoproteins: Nature's Multifunctional Nanoparticles. ACS Nano (2016) 0.87
Nanotechnology: Future of Oncotherapy. Clin Cancer Res (2015) 0.86
Histamine release associated with intravenous delivery of a fluorocarbon-based sevoflurane emulsion in canines. J Pharm Sci (2011) 0.85
Zwitterionic gel encapsulation promotes protein stability, enhances pharmacokinetics, and reduces immunogenicity. Proc Natl Acad Sci U S A (2015) 0.84
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come. Pharmacol Rev (2016) 0.84
The use of convection-enhanced delivery with liposomal toxins in neurooncology. Toxins (Basel) (2011) 0.83
Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy. Ther Deliv (2012) 0.83
Impact of large aggregated uricases and PEG diol on accelerated blood clearance of PEGylated canine uricase. PLoS One (2012) 0.82
Poly(trehalose): sugar-coated nanocomplexes promote stabilization and effective polyplex-mediated siRNA delivery. J Am Chem Soc (2013) 0.82
Theranostic nanoparticles carrying doxorubicin attenuate targeting ligand specific antibody responses following systemic delivery. Theranostics (2015) 0.82
Interleukin-10: an anti-inflammatory marker to target atherosclerotic lesions via PEGylated liposomes. Mol Pharm (2012) 0.81
Fatty acids as therapeutic auxiliaries for oral and parenteral formulations. Adv Drug Deliv Rev (2012) 0.81
A novel submicron emulsion system loaded with vincristine-oleic acid ion-pair complex with improved anticancer effect: in vitro and in vivo studies. Int J Nanomedicine (2013) 0.81
Nanobiotechnology for the Therapeutic Targeting of Cancer Cells in Blood. Cell Mol Bioeng (2015) 0.80
Zwitterionic amphiphile coated magnetofluorescent nanoparticles - synthesis, characterization and tumor cell targeting. J Mater Chem B Mater Biol Med (2015) 0.80
Overcoming the challenges in the effective delivery of chemotherapies to CNS solid tumors. Ther Deliv (2010) 0.78
Drug carriers based on highly protein-resistant materials for prolonged in vivo circulation time. Regen Biomater (2015) 0.78
Engineered metal based nanoparticles and innate immunity. Clin Mol Allergy (2015) 0.78
Accelerated Blood Clearance Phenomenon Reduces the Passive Targeting of PEGylated Nanoparticles in Peripheral Arterial Disease. ACS Appl Mater Interfaces (2016) 0.77
Gene therapy for the treatment of Parkinson's disease: the nature of the biologics expands the future indications. Pharmaceuticals (Basel) (2012) 0.77
Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer. Int J Nanomedicine (2012) 0.77
Systemic siRNA Delivery via Peptide-Tagged Polymeric Nanoparticles, Targeting PLK1 Gene in a Mouse Xenograft Model of Colorectal Cancer. Int J Biomater (2013) 0.77
Trehalose-Based Block Copolycations Promote Polyplex Stabilization for Lyophilization and in Vivo pDNA Delivery. ACS Biomater Sci Eng (2015) 0.76
Understanding the immunogenicity and antigenicity of nanomaterials: Past, present and future. Toxicol Appl Pharmacol (2016) 0.76
Accelerated drug release and clearance of PEGylated epirubicin liposomes following repeated injections: a new challenge for sequential low-dose chemotherapy. Int J Nanomedicine (2013) 0.76
Cytofectin amine head group modification and degree of liposome pegylation: factors influencing gene transfer. Indian J Pharm Sci (2011) 0.75
Exosomes and breast cancer: a comprehensive review of novel therapeutic strategies from diagnosis to treatment. Cancer Gene Ther (2016) 0.75
Solid tumor-targeting theranostic polymer nanoparticle in nuclear medicinal fields. ScientificWorldJournal (2014) 0.75
Environmental Immunology: Lessons Learned from Exposure to a Select Panel of Immunotoxicants. J Immunol (2016) 0.75
Maximizing the Supported Bilayer Phenomenon: Liposomes Comprised Exclusively of PEGylated Phospholipids for Enhanced Systemic and Lymphatic Delivery. ACS Appl Mater Interfaces (2016) 0.75
Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J Control Release (2006) 1.36
PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J Control Release (2007) 1.34
Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J Control Release (2007) 1.27
Liposome clearance. Biosci Rep (2002) 1.25
Accelerated blood clearance phenomenon upon repeated injection of PEG-modified PLA-nanoparticles. Pharm Res (2009) 1.23
The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage. J Control Release (2013) 1.16
Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J Control Release (2005) 1.16
Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int J Pharm (2006) 1.10
Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. J Control Release (2006) 1.09
Cationic liposome-mediated gene delivery: biophysical study and mechanism of internalization. Arch Biochem Biophys (2003) 1.07
Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J Control Release (2006) 1.02
T cell-independent B cell response is responsible for ABC phenomenon induced by repeated injection of PEGylated liposomes. Int J Pharm (2010) 0.99
CpG motifs in pDNA-sequences increase anti-PEG IgM production induced by PEG-coated pDNA-lipoplexes. J Control Release (2009) 0.98
Lipoplex size determines lipofection efficiency with or without serum. Mol Membr Biol (2003) 0.98
Accelerated clearance of PEGylated liposomes in rats after repeated injections. J Control Release (2003) 0.98
Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model. J Control Release (2009) 0.96
Particle size-dependent triggering of accelerated blood clearance phenomenon. Int J Pharm (2008) 0.94
Encapsulation of an antivasospastic drug, fasudil, into liposomes, and in vitro stability of the fasudil-loaded liposomes. Int J Pharm (2002) 0.94
Evasion of the accelerated blood clearance phenomenon by coating of nanoparticles with various hydrophilic polymers. Biomacromolecules (2010) 0.94
Quantitative analysis of correlation between number of nuclear plasmids and gene expression activity after transfection with cationic liposomes. Pharm Res (2002) 0.94
Anti-PEG IgM Response against PEGylated Liposomes in Mice and Rats. Pharmaceutics (2010) 0.93
A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA. Mol Ther (2011) 0.90
Complex formation with plasmid DNA increases the cytotoxicity of cationic liposomes. Biol Pharm Bull (2007) 0.89
Targeting anticancer drugs to tumor vasculature using cationic liposomes. Pharm Res (2010) 0.89
Accelerated clearance of a second injection of PEGylated liposomes in mice. Int J Pharm (2003) 0.88
Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. Int J Pharm (2007) 0.88
Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in rats. J Control Release (2005) 0.87
The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats. J Control Release (2007) 0.87
Oxaliplatin targeting to angiogenic vessels by PEGylated cationic liposomes suppresses the angiogenesis in a dorsal air sac mouse model. J Control Release (2008) 0.86
Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs. Int J Pharm (2012) 0.86
Effect of the physicochemical properties of initially injected liposomes on the clearance of subsequently injected PEGylated liposomes in mice. J Control Release (2004) 0.86
Anti-polyethyleneglycol antibody response to PEGylated substances. Biol Pharm Bull (2013) 0.86
Recent advances in tumor vasculature targeting using liposomal drug delivery systems. Expert Opin Drug Deliv (2009) 0.85
Efficient gene expression in megakaryocytic cell line using nucleofection. Int J Pharm (2007) 0.85
Optimized PEGylated adenovirus vector reduces the anti-vector humoral immune response against adenovirus and induces a therapeutic effect against metastatic lung cancer. Biol Pharm Bull (2010) 0.84
Combination therapy of metronomic S-1 dosing with oxaliplatin-containing polyethylene glycol-coated liposome improves antitumor activity in a murine colorectal tumor model. Cancer Sci (2010) 0.84
Intravenous administration of polyethylene glycol-coated (PEGylated) proteins and PEGylated adenovirus elicits an anti-PEG immunoglobulin M response. Biol Pharm Bull (2012) 0.83
Global gene expression profiling in cultured cells is strongly influenced by treatment with siRNA-cationic liposome complexes. Pharm Res (2008) 0.83
Disappearance of the angiogenic potential of endothelial cells caused by Argonaute2 knockdown. Biochem Biophys Res Commun (2008) 0.83
Sequential administration with oxaliplatin-containing PEG-coated cationic liposomes promotes a significant delivery of subsequent dose into murine solid tumor. J Control Release (2009) 0.83
Anti-PEG IgM production by siRNA encapsulated in a PEGylated lipid nanocarrier is dependent on the sequence of the siRNA. J Control Release (2011) 0.83
Safe and efficient drug delivery system with liposomes for intrathecal application of an antivasospastic drug, fasudil. Biol Pharm Bull (2006) 0.82
Alteration of tumor microenvironment for improved delivery and intratumor distribution of nanocarriers. Biol Pharm Bull (2013) 0.82
Development of pH-sensitive liposomes that efficiently retain encapsulated doxorubicin (DXR) in blood. Int J Pharm (2005) 0.81
Transport of PEGylated liposomes from the splenic marginal zone to the follicle in the induction phase of the accelerated blood clearance phenomenon. Immunobiology (2012) 0.81
Anti-angiogenic therapy via cationic liposome-mediated systemic siRNA delivery. Int J Pharm (2011) 0.81
Effect of siRNA in PEG-coated siRNA-lipoplex on anti-PEG IgM production. J Control Release (2009) 0.81
A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model. Int J Pharm (2007) 0.81
Agitation during lipoplex formation improves the gene knockdown effect of siRNA. Int J Pharm (2011) 0.80
Multiple administration of PEG-coated liposomal oxaliplatin enhances its therapeutic efficacy: a possible mechanism and the potential for clinical application. Int J Pharm (2012) 0.80
The gene-silencing effect of siRNA in cationic lipoplexes is enhanced by incorporating pDNA in the complex. Int J Pharm (2006) 0.80
Complexation of siRNA and pDNA with cationic liposomes: the important aspects in lipoplex preparation. Methods Mol Biol (2010) 0.80
Gene expression analysis during platelet-like particle production in phorbol myristate acetate-treated MEG-01 cells. Biol Pharm Bull (2009) 0.80
Use of polyglycerol (PG), instead of polyethylene glycol (PEG), prevents induction of the accelerated blood clearance phenomenon against long-circulating liposomes upon repeated administration. Int J Pharm (2013) 0.79
[Elucidation of accelerated blood clearance phenomenon caused by repeat injection of PEGylated nanocarriers]. Yakugaku Zasshi (2009) 0.79
An assessment of relative transcriptional availability from nonviral vectors. Int J Pharm (2004) 0.79
Suppression of immune response by antigen-modified liposomes encapsulating model agents: a novel strategy for the treatment of allergy. J Control Release (2013) 0.79
Increased gene expression by cationic liposomes (TFL-3) in lung metastases following intravenous injection. Biol Pharm Bull (2005) 0.79
In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1-MMP). Biol Pharm Bull (2007) 0.78
Cell type-specific gene expression, mediated by TFL-3, a cationic liposomal vector, is controlled by a post-transcription process of delivered plasmid DNA. Int J Pharm (2004) 0.78
Relationship between the concentration of anti-polyethylene glycol (PEG) immunoglobulin M (IgM) and the intensity of the accelerated blood clearance (ABC) phenomenon against PEGylated liposomes in mice. Biol Pharm Bull (2015) 0.78
Synergistic antitumor activity of metronomic dosing of cyclophosphamide in combination with doxorubicin-containing PEGylated liposomes in a murine solid tumor model. J Control Release (2008) 0.78
Ex-vivo/in-vitro anti-polyethylene glycol (PEG) immunoglobulin M production from murine splenic B cells stimulated by PEGylated liposome. Biol Pharm Bull (2013) 0.78
pH-sensitive liposomes in nuclear targeting of macromolecules. Methods Enzymol (2003) 0.77
The accelerated clearance on repeated injection of pegylated liposomes in rats: laboratory and histopathological study. Cell Mol Biol Lett (2002) 0.77
Comparative analysis of in vitro and in vivo pharmacokinetic parameters related to individual variability of GTS-21 in canine. Drug Metab Pharmacokinet (2002) 0.77
Anti-PEG IgM production via a PEGylated nano-carrier system for nucleic acid delivery. Methods Mol Biol (2013) 0.77
The co-delivery of oxaliplatin abrogates the immunogenic response to PEGylated siRNA-lipoplex. Pharm Res (2013) 0.76
Agitation during lipoplex formation harmonizes the interaction of siRNA to cationic liposomes. Int J Pharm (2012) 0.76
Immunoliposomal drug-delivery system targeting lectin-like oxidized low-density lipoprotein receptor-1 for carotid plaque lesions in rats. J Neurosurg (2011) 0.76
Stimulatory effect of polyethylene glycol (PEG) on gene expression in mouse liver following hydrodynamics-based transfection. J Gene Med (2006) 0.76
Tumor-type-dependent vascular permeability constitutes a potential impediment to the therapeutic efficacy of liposomal oxaliplatin. Eur J Pharm Biopharm (2012) 0.76
Inducing effect of liposomalization on the transdermal delivery of hydrocortisone: creation of a drug supersaturated state. J Control Release (2006) 0.76
Abrogation of the accelerated blood clearance phenomenon by SOXL regimen: promise for clinical application. Int J Pharm (2012) 0.76
Application of polyglycerol coating to plasmid DNA lipoplex for the evasion of the accelerated blood clearance phenomenon in nucleic acid delivery. J Pharm Sci (2013) 0.76
[Accelerated blood clearance (ABC) phenomenon induced by administration of PEGylated liposome]. Yakugaku Zasshi (2008) 0.75
Effect of cationic liposomes in an in vitro transcription and translation system. Biol Pharm Bull (2002) 0.75
Co-administration of tacrolimus suppresses pharmacokinetic modulation of multiple subcutaneously administered human interferon-alpha in Beagle dogs. Drug Metab Pharmacokinet (2010) 0.75
Electrophoretic behavior of plasmid DNA in the presence of various intercalating dyes. J Chromatogr A (2006) 0.75
[Development of siRNA delivery strategy by active control of tumor microenvironment]. Yakugaku Zasshi (2013) 0.75
Lactoferrin inhibits platelet production from human megakaryocytes in vitro. Biol Pharm Bull (2008) 0.75
Argonaute2 is a potential target for siRNA-based cancer therapy for HT1080 human fibrosarcoma. Drug Deliv Transl Res (2011) 0.75
Improved intratumoral delivery of PEG-coated siRNA-lipoplexes by combination with metronomic S-1 dosing in a murine solid tumor model. Drug Deliv Transl Res (2012) 0.75
Culture time-dependent gene expression in isolated primary cultured rat hepatocytes by transfection with the cationic liposomal vector TFL-3. Biol Pharm Bull (2003) 0.75
Combination therapy with metronomic S-1 dosing and oxaliplatin-containing PEG-coated cationic liposomes in a murine colorectal tumor model: synergy or antagonism? Int J Pharm (2012) 0.75
Selective delivery of oxaliplatin to tumor tissue by nanocarrier system enhances overall therapeutic efficacy of the encapsulated oxaliplatin. Biol Pharm Bull (2014) 0.75
Combined effect of liposomalization and addition of glycerol on the transdermal delivery of isosorbide 5-nitrate in rat skin. Int J Pharm (2008) 0.75
Pharmacokinetics of targeting with liposomes. Crit Rev Ther Drug Carrier Syst (2002) 0.75
HEPC-based liposomes trigger cytokine release from peripheral blood cells: effects of liposomal size, dose and lipid composition. Int J Pharm (2002) 0.75
Gene expression in primary cultured mouse hepatocytes with a cationic liposomal vector, TFL-3: comparison with rat hepatocytes. Biol Pharm Bull (2005) 0.75
Effect of co-administration of tacrolimus on the pharmacokinetics of multiple subcutaneous administered interferon-alpha in rats. Pharm Res (2009) 0.75